CRMD announced DefenCath revenue 85M for Q3 which is up 114% QoQ. This is much higher than I had expected based on their guidance. Their most recent guidance was at 130-145M for the second half of 2025 and so I was thinking in the 60-70M range for Q3 as they ramped up their distribution.
Looking forward to the earnings report and the conference call. I will have my eye focused on Gross Margins as well as EBITDA. I do expect a dip in margins as they process the integration of the new company they purchased.
Drew
Long CRMD